<DOC>
	<DOCNO>NCT01449123</DOCNO>
	<brief_summary>The primary objective pilot study explore asthma patient prescribe fix dose combination ( budenosid/formoterol ( Symbicort® ) , salmeterol/fluticasone ( Seretide® ) , beclometasone/formoterol ( Innovair® ) optimal treat regard mannitol challenge test follow reversibility test . The primary endpoint identify asthma patient respond positive negative mannitol challenge test and/or reversibility test . The hypothesis patient well treat .</brief_summary>
	<brief_title>Mannitol Challenge Test Adult Asthma Patients With Fixed Dose Combinations</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Inclusion criterion 1 . Males female , age 1865 year . 2 . Subjects diagnose asthma . 3 . Subjects baseline FEV1 ≥70 % predict value . 4 . Outpatients primary clinic . 5 . Subjects treat fix dose combination least last three month . 6 . Subjects withhold asthma allergy medication accord individual instruction day challenge test . 7 . Subjects able read comprehend Swedish willing sign inform consent . Exclusion Criteria 1 . Subjects evidence respiratory and/or obstructive disease include recent infection/exacerbation . 2 . Subjects treat oral corticosteroid within 4 week ( 28 day ) prior day challenge test . 3 . Any history hypersensitivity mannitol challenge test . 4 . Any contraindication use diagnostic study medication . 5 . Subjects unsuitable reason ( ) opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>mannitol challenge test</keyword>
	<keyword>Sweden</keyword>
	<keyword>primary care</keyword>
</DOC>